Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Debt to Equity (2020 - 2022)

Historic Debt to Equity for SAB Biotherapeutics (SABS) over the last 2 years, with Q4 2022 value amounting to $0.02.

  • SAB Biotherapeutics' Debt to Equity changed N/A to $0.02 in Q4 2022 from the same period last year, while for Dec 2022 it was $0.02, marking a year-over-year change of. This contributed to the annual value of $0.02 for FY2022, which is N/A changed from last year.
  • SAB Biotherapeutics' Debt to Equity amounted to $0.02 in Q4 2022.
  • In the past 5 years, SAB Biotherapeutics' Debt to Equity ranged from a high of $0.02 in Q4 2022 and a low of $0.0 during Q4 2020